The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Breast Neoplasms
  • Neoplasm Recurrence, Local
  • Receptor, ErbB-2
  • Trastuzumab

abstract

  • High rates of locoregional control (5-year rate, 98 %) were observed among patients who received trastuzumab and mastectomy ± PMRT. Trastuzumab decreased LRR in HER2-positive women who received mastectomy and PMRT, suggesting that the largest benefit is seen in a higher-risk subset of patients.

publication date

  • August 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1245/s10434-014-4321-2

PubMed ID

  • 25564167

Additional Document Info

start page

  • 2517

end page

  • 25

volume

  • 22

number

  • 8